Clinical Trial Update: Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial results for GTx-024 in ER+/AR+ breast cancer have been completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• GTx-024

Snippet

Sponsor: GTx | Conditions: ER+ and AR+ Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-12-09